1. Metabolic Enzyme/Protease Autophagy Anti-infection
  2. Carbonic Anhydrase Autophagy Bacterial
  3. Acetazolamide

Acetazolamide  (Synonyms: 乙酰唑胺)

目录号: HY-B0782 纯度: 99.89%
COA 产品使用指南

Acetazolamide 是一种碳酸酐酶 (CA) IX 抑制剂,对 hCA IXIC50 为 30 nM。Acetazolamide 具有利尿、抗高血压和抗淋球菌活性。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Acetazolamide Chemical Structure

Acetazolamide Chemical Structure

CAS No. : 59-66-5

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥500
In-stock
500 mg ¥400
In-stock
1 g ¥500
In-stock
5 g ¥800
In-stock
10 g   询价  
50 g   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of Acetazolamide:

查看 Carbonic Anhydrase 亚型特异性产品:

  • 生物活性

  • 实验参考方法

  • 纯度 & 产品资料

  • 参考文献

生物活性

Acetazolamide is a carbonic anhydrase (CA) IX inhibitor with an IC50 of 30 nM for hCA IX. Acetazolamide has diuretic, antihypertensive and anti-gonococcal activities[1][4][5][6].

IC50 & Target

CA Ⅸ

 

细胞效力
(Cellular Effect)
Cell Line Type Value Description References
HeLa IC50
2.83 μM
Compound: AZA
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs under hypoxia condition by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs under hypoxia condition by MTT assay
[PMID: 31901743]
HeLa IC50
7.82 μM
Compound: AZA
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs under normaxia condition by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs under normaxia condition by MTT assay
[PMID: 31901743]
HT-29 IC50
> 100 μM
Compound: AAZ
Cytotoxicity against human HT-29 cells after 96 hrs under hypoxic condition by MTT assay
Cytotoxicity against human HT-29 cells after 96 hrs under hypoxic condition by MTT assay
[PMID: 29649740]
HT-29 IC50
> 100 μM
Compound: AAZ
Cytotoxicity against human HT-29 cells after 96 hrs under normoxic condition by MTT assay
Cytotoxicity against human HT-29 cells after 96 hrs under normoxic condition by MTT assay
[PMID: 29649740]
HT-29 IC50
53.78 μM
Compound: AAZ
Cytotoxicity in human HT-29 cells assessed as reduction in cell viability incubated for 24 hrs under hypoxic condition by MTT assay
Cytotoxicity in human HT-29 cells assessed as reduction in cell viability incubated for 24 hrs under hypoxic condition by MTT assay
[PMID: 31542715]
MDA-MB-231 IC50
> 100 μM
Compound: AAZ
Cytotoxicity against human MDA-MB-231 cells after 96 hrs under hypoxic condition by MTT assay
Cytotoxicity against human MDA-MB-231 cells after 96 hrs under hypoxic condition by MTT assay
[PMID: 29649740]
MDA-MB-231 IC50
> 100 μM
Compound: AAZ
Cytotoxicity against human MDA-MB-231 cells after 96 hrs under normoxic condition by MTT assay
Cytotoxicity against human MDA-MB-231 cells after 96 hrs under normoxic condition by MTT assay
[PMID: 29649740]
WI-38 IC50
14.45 μM
Compound: AZA
Cytotoxicity against human WI-38 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human WI-38 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 31901743]
体外研究
(In Vitro)

Acetazolamide 抑制 hCA II 的 IC50 为 130 nM[1].
Acetazolamide (Ace) 是一种小型杂环磺酰胺,与各种碳酸酐酶高亲和力结合,表现为碳酸酐酶 (CA) 抑制剂[2].
与对照组相比,高浓度 Acetazolamide (AceH,50 nM) 、顺铂 (Cis,1 μg/mL) 和低浓度 Acetazolamide (AceL,10 nM) 联合处理显著降低 Hep-2 细胞活力[2].
Acetazolamide/Cis 联合治疗显著提高 P53 表达水平,两种剂量组合 (AceL+Cis 和 AceH+Cis) 均显著提高 P53 蛋白表达,相较对照组明显升高。Ace/Cis 联合治疗显著降低 bcl-2/bax 表达比,并提高 caspase-3 蛋白水平,与对照组相比差异显著。AceL、AceH、Cis 和 AceL+Cis 处理均显著降低 bcl-2/bax 比值[2].
Ace 和 Cis 联合治疗显著诱导 Hep-2 细胞凋亡[2].
Ace 和 Cis 联合治疗显著减少 Hep-2 细胞中 AQP1 mRNA 的表达水平。AceH 和 AceL+Cis 处理均降低了与对照组相比的 aquaporin-1 (AQP1) mRNA 表达水平[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Acetazolamide (40 mg/kg) 显著增强 MS-275 对神经母细胞瘤 (NB) SH-SY5Y 异种移植瘤中肿瘤发生的抑制作用[3][1234]Acetazolamide (40 mg/kg) 和/或 MS-275 治疗可降低 NB SH-SY5Y 异种移植瘤中 HIF1-α 和 CAIX 的表达[3][1234]Acetazolamide (40 mg/kg)、MS-275 和Acetazolamide +MS-275 可降低 NB SH-SY5Y 异种移植瘤中有丝分裂和增殖标志物的表达[3][1234]Acetazolamide (50 mg/kg;口服,连续 3 天) 可显著减少感染小鼠阴道内的淋球菌负荷 90%[6]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial
分子量

222.25

Formula

C4H6N4O3S2

CAS 号
性状

固体

颜色

White to off-white

中文名称

乙酰唑胺;醋氮酰胺

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 1 year
-20°C 6 months
溶解性数据
细胞实验: 

DMSO 中的溶解度 : 50 mg/mL (224.97 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

H2O 中的溶解度 : < 0.1 mg/mL (insoluble)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 4.4994 mL 22.4972 mL 44.9944 mL
5 mM 0.8999 mL 4.4994 mL 8.9989 mL
查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 1 year; -20°C, 6 months。-80°C储存时,请在1年内使用, -20°C储存时,请在6个月内使用。

  • 摩尔计算器

  • 稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量
=
浓度
×
体积
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start)

C1

×
体积 (start)

V1

=
浓度 (final)

C2

×
体积 (final)

V2

动物实验:

请根据您的 实验动物和给药方式 选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 方案 一

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (11.25 mM); 澄清溶液

    此方案可获得 ≥ 2.5 mg/mL(饱和度未知)的澄清溶液。

    1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;再向上述体系中加入 50 μL Tween-80,混合均匀;然后再继续加入 450 μL 生理盐水 定容至 1 mL

    生理盐水的配制:将 0.9 g 氯化钠,溶解于 ddH₂O 并定容至 100 mL,可以得到澄清透明的生理盐水溶液。
  • 方案 二

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (11.25 mM); 澄清溶液

    此方案可获得 ≥ 2.5 mg/mL(饱和度未知)的澄清溶液。

    1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液 中,混合均匀。

    2 g SBE-β-CD(磺丁基醚 β-环糊精)粉末定容于 10 mL 的生理盐水中,完全溶解至澄清透明。

以下溶解方案,请直接配制工作液。建议现用现配,在短期内尽快用完。 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比; 如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶。

  • 方案 一

    请依序添加每种溶剂: PBS

    Solubility: 1.96 mg/mL (8.82 mM); 澄清溶液; 超声助溶 (<60°C)

动物溶解方案计算器
请输入动物实验的基本信息:

给药剂量

mg/kg

动物的平均体重

g

每只动物的给药体积

μL

动物数量

由于实验过程有损耗,建议您多配一只动物的量
请输入您的动物体内配方组成:
%
DMSO +
+
%
Tween-80 +
%
Saline
如果您的动物是免疫缺陷鼠或者体弱鼠,建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。
方案所需 助溶剂 包括:DMSO ,均可在 MCE 网站选购。 Tween 80,均可在 MCE 网站选购。
计算结果
工作液所需浓度 : mg/mL
储备液配制方法 : mg 药物溶于 μL  DMSO(母液浓度为 mg/mL)。
您所需的储备液浓度超过该产品的实测溶解度,以下方案仅供参考,如有需要,请与 MCE 中国技术支持联系。
动物实验体内工作液的配制方法 : 取 μL DMSO 储备液,加入 μL  μL ,混合均匀至澄清,再加 μL Tween 80,混合均匀至澄清,再加 μL 生理盐水
连续给药周期超过半月以上,请谨慎选择该方案。
请确保第一步储备液溶解至澄清状态,从左到右依次添加助溶剂。您可采用超声加热 (超声清洗仪,建议频次 20-40 kHz),涡旋吹打等方式辅助溶解。
纯度 & 产品资料

纯度: 99.89%

参考文献
Cell Assay

Cell Viability Assay[2]
Cell line: Hep-2 cells and HUVECs
Concentration: 10 nM and 50 nM
Incubation time: 48 h
Assay: The cell viability of Hep-2 cells and HUVECs is measured by MTT assay. Hep-2 cells and HUVECs in logarithmic growth phase are plated in 96-well plates. Following 48 h of drug treatment as indicated, 200 µL MTT (5 mg/mL) is added to each well. Cells are incubated with the MTT solution at 37°C for 4 h. Then, 150 µL DMSO is added for 5 min. The optical density (OD) values are measured at 490 nm with a Versamax Microplate reader.
Note: Combined treatment effectively reduced viability in Hep-2 cells.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration

In vivo studies[3]
Animal model: 4-6 weeks-old female NOD/SCID mice
Dosage: 40 mg/kg, intraperitoneal injection, every day for 2 weeks
Administration: Mice are randomized into four groups (5 mice per group). The control and treatment groups receive intraperitoneal injections of vehicle (PBS) or Acetazolamide (40 mg/kg), MS-275 (20 mg/kg) or the combination, respectively, every day for 2 weeks. Experiments are terminated when tumor sizes exceed 2 cm3 in volume or animals show signs of morbidity. Tumor diameters are measured on a daily basis until termination.
Note: Inhibited tumor growth of NB xenografts with significant anti-tumor growth potentiation effect.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献

完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 1 year; -20°C, 6 months。-80°C储存时,请在1年内使用, -20°C储存时,请在6个月内使用。

可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 4.4994 mL 22.4972 mL 44.9944 mL 112.4859 mL
5 mM 0.8999 mL 4.4994 mL 8.9989 mL 22.4972 mL
10 mM 0.4499 mL 2.2497 mL 4.4994 mL 11.2486 mL
15 mM 0.3000 mL 1.4998 mL 2.9996 mL 7.4991 mL
20 mM 0.2250 mL 1.1249 mL 2.2497 mL 5.6243 mL
25 mM 0.1800 mL 0.8999 mL 1.7998 mL 4.4994 mL
30 mM 0.1500 mL 0.7499 mL 1.4998 mL 3.7495 mL
40 mM 0.1125 mL 0.5624 mL 1.1249 mL 2.8121 mL
50 mM 0.0900 mL 0.4499 mL 0.8999 mL 2.2497 mL
60 mM 0.0750 mL 0.3750 mL 0.7499 mL 1.8748 mL
80 mM 0.0562 mL 0.2812 mL 0.5624 mL 1.4061 mL
100 mM 0.0450 mL 0.2250 mL 0.4499 mL 1.1249 mL
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
Acetazolamide
目录号:
HY-B0782
需求量: